AU1395499A - Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells - Google Patents

Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells

Info

Publication number
AU1395499A
AU1395499A AU13954/99A AU1395499A AU1395499A AU 1395499 A AU1395499 A AU 1395499A AU 13954/99 A AU13954/99 A AU 13954/99A AU 1395499 A AU1395499 A AU 1395499A AU 1395499 A AU1395499 A AU 1395499A
Authority
AU
Australia
Prior art keywords
cells
tumors
vivo
activated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13954/99A
Inventor
Carl June
David N. Liebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of AU1395499A publication Critical patent/AU1395499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
AU13954/99A 1997-11-10 1998-11-10 Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells Abandoned AU1395499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6503197P 1997-11-10 1997-11-10
US60065031 1997-11-10
PCT/US1998/023954 WO1999024045A1 (en) 1997-11-10 1998-11-10 Methods for treatment of tumors and tumor cells using ex vivo activated t cells

Publications (1)

Publication Number Publication Date
AU1395499A true AU1395499A (en) 1999-05-31

Family

ID=22059894

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13954/99A Abandoned AU1395499A (en) 1997-11-10 1998-11-10 Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells

Country Status (6)

Country Link
EP (1) EP1030674A1 (en)
JP (1) JP2001522806A (en)
AU (1) AU1395499A (en)
CA (1) CA2309206A1 (en)
NO (1) NO20002412L (en)
WO (1) WO1999024045A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
ES2602145T3 (en) 2002-09-06 2017-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with antigen specific lymphocytes selected in vitro after nonmyeloablative lymphocyte suppressive chemotherapy
JP2006524991A (en) * 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド Method for producing and isolating antigen-specific T cells
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007525225A (en) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド Method for preparing T cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2010032444A (en) * 2008-07-30 2010-02-12 Olympus Corp Living tissue treatment device
SG194753A1 (en) 2011-05-03 2013-12-30 Immunovative Therapies Ltd Induction of il-12 using immunotherapy
SG194774A1 (en) 2011-05-03 2013-12-30 Immunovative Therapies Ltd Methods for handling biological drugs containing living cells
CA3033911A1 (en) 2016-08-26 2018-03-01 Juno Therapeutics, Inc. Methods of enumerating particles present in a cell composition
US11766039B2 (en) 2017-06-28 2023-09-26 Sci-Group As Freezing of biological material
WO2019169194A1 (en) * 2018-02-28 2019-09-06 Juno Therapeutics, Inc. Methods for detecting particles present in a cell composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341374C (en) * 1986-11-13 2002-07-09 Alan N. Houghton Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
EP0637963B1 (en) * 1992-04-07 2004-08-04 The Regents of the University of Michigan Cd28 pathway immunoregulation
WO1994029436A1 (en) * 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
EP0852618A1 (en) * 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease

Also Published As

Publication number Publication date
EP1030674A1 (en) 2000-08-30
WO1999024045A1 (en) 1999-05-20
JP2001522806A (en) 2001-11-20
NO20002412L (en) 2000-07-07
NO20002412D0 (en) 2000-05-09
CA2309206A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
AU1939200A (en) Electrochemical treatment of malignant tumors
AU2022999A (en) Methods and apparatus for perfusion of isolated tissue structure
AU2160297A (en) Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
AU4655296A (en) Compositions and methods for treating tumor cells
EP0963207A4 (en) Il-12 gene therapy of tumors
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU8397998A (en) Method and apparatus for radiation and hyperthermia therapy of tumors
AU1967501A (en) Device and method for improved diagnosis and treatment of cancer
AU3683800A (en) Device for the therapeutic and cosmetic photo-processing of biological tissues and method for using the same
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU4473596A (en) Methods of human prostate cancer diagnosis
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2701195A (en) Methods for treating cancer and other cell proliferative diseases
EP1119365A4 (en) Composition and method of using tumor cells
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU1395499A (en) Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells
AU4913197A (en) Apparatus for stimulating living tissue
AU4003597A (en) Methods of diagnosing and treating cancer
AU5300396A (en) Radiation enhanced gene therapy for treatment of tumors
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
AU4608296A (en) Methods and compositions for treatment of solid tumors in vivo
AU8068198A (en) Methods for treating human cancers
AU5333298A (en) Compositions and methods for tumour therapy
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU1310697A (en) Magnetic substance for local hyperthermal treatment of tumours, in particular smaller tumours

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase